A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are bein...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of Cancer Research and Therapy 2016/01/13, Vol.24(1), pp.17-22
Hauptverfasser: Ishibashi, Keiichiro, Kumamoto, Kensuke, Koda, Keiji, Kato, Hiroyuki, Nishimura, Genichi, Yoshimatsu, Kazuhiko, Yokomizo, Hajime, Ooki, Shinji, Tanaka, Soichi, Asano, Michio, Yokoyama, Masaru, Kawada, Tomoyuki, Ishida, Hideyuki
Format: Artikel
Sprache:eng
Schlagworte:
adjuvant chemotherapy
colon cancer
oxaliplatin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.
ISSN:1344-6835
1880-5469
DOI:10.4993/acrt.24.17